Drug Trial Radar · NCT06755944
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
360
Actual
Start
Dec 15, 2024
Primary completion
Jun 9, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ⅱb/Ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets, a novel oral neuroprotective agent, and explore the dose-response relationship in patients with acute ischemic stroke. In the Phase Ⅱb stage, 360 eligible subjects were enrolled and randomly assigned to four XY03-EA dose groups and one placebo group in a 1:1:1:1:1 ratio. The primary endpoint was the proportion of patients with a modified Rankin Scale (mRS) score ≤ 1 at Day 90 after the start of study treatment.
Conditions
- Stroke, Ischemic
Interventions
XY03-EA 150 mg (per dose)Drug
XY03-EA tablets, 150 mg/tablet, 1 tablet orally, three times daily (Tid), for 90 days
XY03-EA 300 mg (Regimen A)Drug
XY03-EA tablets, 150 mg/tablet, 2 tablets orally, Tid, for 90 consecutive days
XY03-EA 300 mg (Regimen B)Drug
XY03-EA tablets, 150 mg/tablet, 2 tablets orally, Tid, from Day 1 to Day 14
XY03-EA 450 mg (per dose)Drug
XY03-EA tablets, 150 mg/tablet, 3 tablets orally, Tid, for 90 days
Matching PlaceboDrug
Matching placebo tablets, orally, Tid, for 90 days (or as specified per arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with Modified Rankin Scale (mRS) score ≤ 1 point at 90 days after administration.Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shijiazhuang Yiling Pharmaceutical Co., Ltd
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.